No Data
No Data
Omeros Receives Rare Pediatric Disease Designation for Zaltenibart From FDA
Express News | FDA Grants Rare Pediatric Disease Designation to Omeros’ Masp-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
Needham Sticks to Its Hold Rating for Omeros (OMER)
Omeros: Q2 Earnings Snapshot
Express News | Omeros Q2 2024 GAAP EPS $(0.97) Beats $(1.14) Estimate
Omeros | 10-Q: Q2 2024 Earnings Report
No Data
No Data